Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
1,206
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design

Anita Kumara Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesCorrespondence[email protected]
View further author information
,
Carla Casulob Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, United StatesView further author information
,
Erel Joffea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesORCID Iconhttps://orcid.org/0000-0002-7883-289XView further author information
ORCID Icon,
Craig MoskowitzView further author information
,
John Gerecitanoa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Alison Moskowitza Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Anas Younesa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Pamela Drullinskya Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Esther Drillc Epidemiology and Biostatistics, Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Morgan Chomaa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Clare Grievea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Ashlee Josepha Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesORCID Iconhttps://orcid.org/0000-0003-1699-5666View further author information
ORCID Icon,
Leana Laraquea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Dylan Schicka Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
,
Andrew Zelenetza Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesORCID Iconhttps://orcid.org/0000-0003-1403-6883View further author information
ORCID Icon &
Paul Hamlina Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
 show all
Pages 2889-2896 | Received 28 Mar 2022, Accepted 26 Jul 2022, Published online: 16 Aug 2022

References

  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
  • Flinn IW, van der Jagt R, Kahl B, et al. First-Line treatment of patients with indolent Non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year follow-up study. J Clin Oncol. 2019;37:984–991.
  • Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800.
  • Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094–1100.
  • Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755.
  • Maloney DG, Ogura M, Fukuhara N, et al. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv. 2020;4:3886–3893.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss group for clinical cancer research (SAKK). Ann Oncol. 2000;11(Suppl 1):123–126.
  • Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss group for clinical cancer research (SAKK). J Clin Oncol. 2005;23:705–711.
  • Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 1999;62:76–82.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383–3389.
  • Gine E, de la Cruz F, Jimenez Ubieto A, et al. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022;40(11):1196–1205.
  • Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–1213.
  • Kumar A, Ying Z, Alperovich A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104:e163–e166.
  • Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28:2489–2495.
  • van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-Cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544–551.
  • Rummel MJ, Janssens A, MacDonald D, et al. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT a + B study). Br J Haematol. 2021;193(6):1123–1133.
  • Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482–2494.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.